| Venkat Patla, MD | |
|
3300 Gallows Rd, Falls Church, VA 22042-3307 | |
| (703) 689-3138 | |
| Not Available |
| Full Name | Venkat Patla |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 42 Years |
| Location | 3300 Gallows Rd, Falls Church, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124038419 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 0101230585 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Inova Fairfax Hospital | Falls church, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northstar Anesthesia Of Virginia, Llc | 6608268826 | 349 |
News Archive
Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.
Doctors across the country are still prescribing higher-dose menopausal hormone therapy pills, despite clinical evidence that low doses and skin patches work just as well and carry fewer health risks. That's what researchers at the Stanford University School of Medicine found in a study that will be published online Dec. 2 in Menopause: The Journal of the North American Menopause Society.
Tools for assisting organizations in their efforts to more accurately calculate, analyze, interpret and communicate the costs and benefits of workplace safety and health programs are featured as part of published proceedings released on July 29th in the National Safety Council's Journal of Safety Research (JSR).
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
› Verified 9 days ago
| Entity Name | American Anesthesiology Of Virginia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417994872 PECOS PAC ID: 6800790023 Enrollment ID: O20031120000429 |
News Archive
Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.
Doctors across the country are still prescribing higher-dose menopausal hormone therapy pills, despite clinical evidence that low doses and skin patches work just as well and carry fewer health risks. That's what researchers at the Stanford University School of Medicine found in a study that will be published online Dec. 2 in Menopause: The Journal of the North American Menopause Society.
Tools for assisting organizations in their efforts to more accurately calculate, analyze, interpret and communicate the costs and benefits of workplace safety and health programs are featured as part of published proceedings released on July 29th in the National Safety Council's Journal of Safety Research (JSR).
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
› Verified 9 days ago
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20040102000644 |
News Archive
Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.
Doctors across the country are still prescribing higher-dose menopausal hormone therapy pills, despite clinical evidence that low doses and skin patches work just as well and carry fewer health risks. That's what researchers at the Stanford University School of Medicine found in a study that will be published online Dec. 2 in Menopause: The Journal of the North American Menopause Society.
Tools for assisting organizations in their efforts to more accurately calculate, analyze, interpret and communicate the costs and benefits of workplace safety and health programs are featured as part of published proceedings released on July 29th in the National Safety Council's Journal of Safety Research (JSR).
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
› Verified 9 days ago
| Entity Name | Northstar Anesthesia Of Virginia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194488791 PECOS PAC ID: 6608268826 Enrollment ID: O20220120002585 |
News Archive
Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.
Doctors across the country are still prescribing higher-dose menopausal hormone therapy pills, despite clinical evidence that low doses and skin patches work just as well and carry fewer health risks. That's what researchers at the Stanford University School of Medicine found in a study that will be published online Dec. 2 in Menopause: The Journal of the North American Menopause Society.
Tools for assisting organizations in their efforts to more accurately calculate, analyze, interpret and communicate the costs and benefits of workplace safety and health programs are featured as part of published proceedings released on July 29th in the National Safety Council's Journal of Safety Research (JSR).
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Venkat Patla, MD 255 W Michigan Ave, Jackson, MI 49201-2218 Ph: (517) 787-6440 | Venkat Patla, MD 3300 Gallows Rd, Falls Church, VA 22042-3307 Ph: (703) 689-3138 |
News Archive
Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.
Doctors across the country are still prescribing higher-dose menopausal hormone therapy pills, despite clinical evidence that low doses and skin patches work just as well and carry fewer health risks. That's what researchers at the Stanford University School of Medicine found in a study that will be published online Dec. 2 in Menopause: The Journal of the North American Menopause Society.
Tools for assisting organizations in their efforts to more accurately calculate, analyze, interpret and communicate the costs and benefits of workplace safety and health programs are featured as part of published proceedings released on July 29th in the National Safety Council's Journal of Safety Research (JSR).
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
› Verified 9 days ago
Jeffrey Scheidlinger, Anesthesiology Medicare: Medicare Enrolled Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-776-3138 | |
Jack A Stabile, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-689-3138 | |
Dr. Steven A Lussos, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-776-3138 | |
Dr. Sabine E Duffy, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-776-3138 Fax: 781-407-0998 | |
Dr. Roger A Denney, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-776-3138 Fax: 540-982-2719 | |
Zhao Yang, M.D., PH.D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-776-3138 | |
Dr. Emma Alvaro Caligtan, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 201 North Washington Street, Falls Church, VA 22046 Phone: 703-237-4020 Fax: 703-536-1395 |